Preliminary evidence of long-term safety and effectiveness of anti-CGRP drugs for migraine prevention in people with comorbid epilepsy: A 52-week follow-up retrospective study.

This study looked at the safety and effectiveness of anti-CGRP drugs for migraine prevention in people with epilepsy. Researchers followed 11 female patients, aged around 35 years, over 52 weeks. These patients had both migraine and epilepsy and were already on stable seizure medications. Initially, they experienced about 18.5 headache days per month. After 24 weeks, this number dropped to 7.6 days, and further decreased to 5.4 days after 52 weeks. Remarkably, 90% of patients reported at least a 50% reduction in headache days by week 24, and this improvement continued to week 52. Additionally, more patients reported a significant reduction in headaches over time. The findings suggest that anti-CGRP therapies can be safe and effective for migraine management in those with epilepsy, providing hope for better treatment options for these patients. Clinical relevance: This research indicates that anti-CGRP drugs may safely reduce migraines in patients with epilepsy, offering potential new treatment strategies for this challenging dual diagnosis.